Related Experiment Video
Updated: Jul 16, 2026
Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
Published on: February 24, 2026
Lost in translation: treatment trials in the SOD1 mouse and in human ALS
1Department of Neurology, Emory University School of Medicine, Woodruff Memorial Building, 1639 Pierce Drive, Atlanta, GA 30322, USA. michael.benatar@emory.edu
Abstract:
Therapeutic success in the superoxide dismutase (SOD1) mouse model of amyotrophic lateral sclerosis (ALS) has not translated into effective therapy for human ALS, calling into question the utility of such preclinical data for identifying therapeutic agents that are worthy of further study in humans. This random effects meta-analysis of treatment trials in the superoxide dismutase (SOD1) mouse was undertaken in order to explore possible reasons for this failure of translational research and to identify potential pharmacological interventions that might be used in either a preventative or therapeutic trial in familial ALS. Among studies in which treatment was initiated presymptomatically, the weighted mean differences (WMDs) comparing the active treatment to control treated animals were 12 days (onset), 13 days (survival) and 5 days (survival interval). Among studies in which treatment was initiated at the time of symptom onset, the WMDs were 15 days (survival) and 8 days (survival interval). Subgroup analysis suggests that drugs such as minocycline and Cox-2 inhibitors with an anti-inflammatory mechanism of action, and anti-oxidative agents such as creatine or the manganese porphyrin AEOL-10150, appear to be the most promising for preventative and therapeutic trials respectively in patients with familial ALS. These conclusions should be tempered by the methodological limitations of the relevant literature.
Insights
Preclinical studies in the superoxide dismutase (SOD1) mouse model of amyotrophic lateral sclerosis (ALS) show limited therapeutic benefits. Meta-analysis suggests anti-inflammatory and anti-oxidative agents may hold promise for familial ALS clinical trials.
Area of Science:
- Neuroscience
- Pharmacology
- Translational Medicine
Background:
- Therapeutic successes in the superoxide dismutase (SOD1) mouse model of amyotrophic lateral sclerosis (ALS) have not translated to human treatments.
- This discrepancy raises questions about the predictive value of preclinical data for human ALS drug development.
Purpose of the Study:
- To explore reasons for the failure of translational research from SOD1 mouse models to human ALS.
- To identify potential pharmacological interventions for preventative or therapeutic trials in familial ALS.
Main Methods:
- A random effects meta-analysis was conducted on treatment trials in the SOD1 mouse model.
- Data were analyzed based on whether treatment initiation was presymptomatic or at symptom onset.
Main Results:
- Presymptomatic treatment showed weighted mean differences (WMDs) of 12 days (onset), 13 days (survival), and 5 days (survival interval).
- Treatment initiated at symptom onset showed WMDs of 15 days (survival) and 8 days (survival interval).
- Subgroup analysis identified minocycline, Cox-2 inhibitors, creatine, and AEOL-10150 as promising agents.
Conclusions:
- Certain anti-inflammatory and anti-oxidative agents show potential for familial ALS trials.
- Methodological limitations in the literature necessitate cautious interpretation of these findings.
